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Abstract
Purpose of Review Spontaneous pneumothoraces can be the presenting phenotype in a variety of different syndromic genetic
conditions. Respiratory physicians therefore have the opportunity to diagnose and manage these patients early to prevent serious
complications associated with these syndromes.
Recent Findings The genetic syndromes that present with pneumothoraces can be split broadly between those resulting from
defective extracellular matrix formation and those caused by defective tumour-suppressor pathways.When connective tissues are
weakened, lifelong surveillance for arterial dilatation can be life-saving as surgical intervention is effective. Long-term aggressive
treatment of blood pressure can also commence, although some controversy surrounds which drugs are most effective and
precisely how these drugs modify disease progression. Rational treatments of syndromes in which tumour suppressor function
is lost are being developed and, in some instances, can already be offered.
Summary Careful clinical assessment of spontaneous pneumothorax may identify an underlying causal condition and facilitate
life-saving intervention. Respiratory physicians must therefore be aware of these diseases and their diagnostic criteria.
Keywords Pneumothorax . Marfan syndrome . Vascular Ehlers Danlos syndrome, vEDS . Loeys-Dietz . Tuberous sclerosis
complex . TSC . Lymphangioleiomyomatosis . Birt-Hogg-Dubé syndrome . Genetics
Introduction
Pneumothorax, the presence of air within the pleural space,
has been a medical diagnosis since Jean Itard coined the term
early in the nineteenth century. When pneumothorax occurs
without obvious lung pathology or trauma, it is termed prima-
ry spontaneous pneumothorax and happens to approximately
1 in 10,000 of the population [1]. A typical patient will be tall
and slender, the so-called asthenic phenotype. Males, who
outnumber females with pneumothorax 3:1, tend to present
in their late teens to late twenties, while the ages of affected
women are more evenly spread from late teens onward [2].
Despite the relative rarity of primary spontaneous pneumo-
thorax, 10% of patients report having an affected family mem-
ber indicating a strong genetic component to this condition
[3]. Such families are said to have ‘familial pneumothorax’,
and unlike sporadic cases, there appears to be a more equal
distribution between males and females [4]. We previously
suggested that familial pneumothoraces be categorised into
those syndromes resulting from a weakened extracellular ma-
trix and those that affect tumour suppressor genes, the former
typically causing emphysematous changes, the latter cause
pulmonary cysts [4].
Familial pneumothorax frequently represents only one part
of a broader syndrome. Given the essential role of connective
tissues in providing structural integrity to organs, it is unsur-
prising that mutations of the extracellular matrix have diverse
effects, in particular, in the cardiovascular system. By contrast,
mutations that impair tumour suppressor pathways permit ex-
cessive cellular proliferation leading to the development of
both benign and malignant neoplasms.
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Targeted preemptive management of individuals with spe-
cific genetic defects can reduce morbidity and mortality, so-
called precision medicine. By helping to identify individuals
with genetic defects, pneumothorax can enable precision med-
icine to be practiced and lead to patient benefit. It is therefore
important that respiratory physicians are able to identify indi-
viduals with a syndromic cause for their pneumothoraces and
ensure onward referral to appropriate specialist healthcare pro-
viders. In this review, we describe the diagnosis and manage-
ment of the most frequently encountered genetic syndromes
linked with the development of pneumothorax.
Connective Tissue Disorders
Marfan Syndrome
Genetics
Marfan syndrome is perhaps one of the best known causes of
familial pneumothorax and has an incidence of 1:5000 to
1:10,000 [5]. It was first described by Antoine Marfan at the
end of the nineteenth century when he treated a young girl
with unusually long thin limbs [6]. Five decades later, a case
of pneumothorax in the context of Marfan syndrome was re-
ported, subsequently followed by many others [7]. Marfan
syndrome is an autosomal dominant disorder and in 1991
three groups simultaneously reported causative mutations in
the FBN1 gene, which encodes the glycoprotein fibrillin-1
[8–10]. In addition to a role in extracellular matrix structure,
fibrillin-1 helps to regulate TGFβ signalling and both of these
functions account for the complex thoracic and extrathoracic
manifestations of the disorder.
Clinical features
FBN1 is a large and highly polymorphic gene, and so sequenc-
ing is a complex and often confusing process [11]. For this
reason, a diagnosis of Marfan syndrome depends on identifi-
cation of its clinical features as laid out by the revised Ghent
nosology (Table 1). The abnormal bone growth first noted by
Marfan over a century ago leads to tall stature, chest wall
abnormalities (pectus carinatum or excavatum), scoliosis and
arachnodactyly. The excessive length of long bones relative to
o the r s , e .g . ve r t eb rae , can make the a rm span
disproportionally long compared with the height. In the respi-
ratory clinic, it is straightforward to measure arm span relative
to height as a screening tool. An arm span that is more than
1.05-fold that of the height raises the possibility of aberrant
bone growth (Table 1, systemic features). Arachnodactyly is
similarly easy to check using two clinical signs: the Walker-
Murdoch sign is positive if the thumb and small finger of one
hand can completely encircle the opposite wrist; Steinberg’s
sign is positive when the patient can adduct the thumb across
the palm sufficiently far that the distal phalanx of the thumb
protrudes when the fingers are closed over it. Ocular manifes-
tations include lens subluxation and retinal detachment, which
can be appreciated by slit-lamp examination. However, the
most clinically significant manifestations ofMarfan syndrome
are its cardiovascular features including cardiomyopathy, mi-
tral or aortic valve degeneration and aortic root dilatation [11].
Pneumothoraces have been estimated to occur in up to 10%
of patients with Marfan syndrome, although their aetiology is
controversial. Although 5–9.6% of Marfan patients have evi-
dence of blebs on CT [5], this is not significantly different to
the general population [12]. It has been theorised that skeletal
deformities may alter the lung parenchymal tension, predis-
posing individuals to pneumothorax [13].
Management
Prompt diagnosis and management are critical to decrease the
risk of life-threatening complications associated with aortic
aneurysms. Annual echocardiography allows monitoring of
the aortic root, although more frequent imaging might be nec-
essary when the aortic root is widening [14]. Therapy with
Table 1 Revised Ghent criteria for the diagnosis of Marfan syndrome.
Adapted from [11]
Marfan syndrome:
Diagnosis requires one of:
(1) Aortic diameter at the sinuses of Valsalva (Z score ≥ 2) AND ectopia
lentis
(2) Aortic diameter at the sinuses of Valsalva (Z score ≥ 2) AND known
disease-associate FBN1 mutation
(3) Aortic diameter at the sinuses of Valsalva (Z score ≥ 2) AND systemic
score* (≥7pts)
(4) Ectopia lentis AND aortic disease-associate FBN1 mutation
(5) Ectopia lentis AND family history of Marfan syndrome
(6) Systemic score (≥ 7 points) AND family history of Marfan syndrome
(7) Aortic diameter at the sinuses of Valsalva (Z ≥ 2 above 20 years old,
≥ 3 below 20 years) AND family history of Marfan syndrome
*Scoring of systemic features:
• Wrist AND thumb sign—3 (wrist OR thumb sign—1)
• Pectus carinatum deformity—2 (pectus excavatum or chest
asymmetry—1)
• Hindfoot deformity—2 (plain pes planus—1)
• Pneumothorax—2
• Dural ectasia—2
• Protrusio acetabuli—2
•Reduced upper segment/lower segment ratio AND increased arm/height
AND no severe scoliosis—1
• Scoliosis or thoracolumbar kyphosis—1
• Reduced elbow extension—1
• Facial features (3/5)—1 (dolichocephaly, enophthalmos, downslanting
palpebral fissures, malar hypoplasia, retrognathia)
• Skin striae—1
• Myopia > 3 diopters—1
• Mitral valve prolapse (all types)—1
Maximum total: 20 points; score ≥ 7 indicates systemic involvement
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beta-blockade was initially shown to slow the rate of aortic
dilatation and reduce complications associated with aortic an-
eurysms [15]; however, metaanalyses have concluded both in
favour and against their use in Marfan syndrome [16, 17]. A
recent Cochrane review determined that while there is evi-
dence that beta-blockers reduce the rate of aortic diameter
change, the quality of evidence is relatively poor [18]. On
balance, until definitive trials can be performed, it is recom-
mended that individuals withMarfan syndrome continue to be
treated with beta-blockade.
Angiotensin receptor blockade has been proposed for the
treatment of patients with Marfan syndrome since; in addition
to beneficial effects on aortic haemodynamics, these drugs
may also inhibit the overactive TGFβ pathway inMarfan syn-
drome. A small-scale study showed benefit of losartan in
slowing aortic-root enlargement in young individuals resistant
to beta-blockers [19]; however, subsequent studies failed to
show a difference between losartan and beta-blockers therapy
in progression of aortic disease [20, 21].
Surgery is indicated if pharmacological treatment fails and
the aortic root dilates to 50 mm (or 45 mm if there is a family
history of dissection or severe aortic regurgitation) [22]. Total
root replacement or valve sparing root replacement can be
performed, the latter having the advantage of sparing the in-
dividual from lifelong anticoagulation. Recent meta-analyses
and systematic reviews showed comparable outcomes be-
tween the two procedures [23, 24], although surgeon experi-
ence and case-specific features mean valve–sparing surgery
will not be appropriate for all patients [23, 25].
Annual ophthalmologic examination has been recom-
mended for individuals with Marfan syndrome [26]. If clini-
cally significant lens subluxation is noted, corrective lenses or
surgical extraction followed by artificial lens replacement can
be offered [26].
Vascular Ehlers-Danlos Syndrome
Genetics
Although “Ehlers-Danlos syndrome” has been recognised
since the 1930s, it is in fact a group of weakly related condi-
tions that share a propensity toward hypermobile joints. At
present, only vascular Ehlers-Danlos syndrome (vEDS or
EDS type 4) is known to be a risk factor for the development
of pneumothorax. vEDS is rare (1 case per 100,000 popula-
tion) but is potentially a more serious connective tissue disor-
der than Marfan syndrome. It is caused by autosomal domi-
nant mutations in the COL3A1 gene, which encodes collagen
type III [27]. This protein is found in many connective tissues
including the pulmonary vasculature and lung parenchyma
[28]. In contrast to Marfan syndrome, molecular testing is
often helpful in establishing a diagnosis of vEDS, but if ge-
netic testing proves negative yet clinical suspicion remains
high, biochemical abnormalities of collagen type III can be
sought using cultured fibroblasts [29].
Clinical features
Diagnostic criteria developed in 2017 advise that vEDS
should be suspected in patients with unexplained arterial an-
eurysms, dissection or rupture; intestinal rupture; uterine rup-
ture during pregnancy; or a family history of vEDS [30].
However, pneumothorax is also a relatively frequent present-
ing feature of vEDS and offers a crucial opportunity to diag-
nose the condition before life-threatening complications occur
[31, 32]. Other pulmonary features of vEDS reflect vascular
fragility with spontaneous haemothorax and haemoptysis.
Radiology may reveal pulmonary cavitation, which often
leads clinicians to suspect pulmonary vasculi t is .
Consequently, a majority of vEDS diagnoses are made only
after lung biopsy shows no vasculitis but evidence of recurrent
haemorrhage, such as haemosiderin-laded macrophages and
fibrous nodules with osseous metaplasia (Fig. 1a) [34].
A diagnosis of vEDS should be suspected clinically in
patients who are hypermobile or have relatives with hypermo-
bility. For this reason, we recommend that Beighton scores are
recorded for all patients with spontaneous pneumothorax
(Table 2). Other more rare skeletal features include clubfoot,
congenital hip dislocation and facial dysmorphism with nar-
row nose, deep-set eyes, micrognathia and thin lips. A simple
dermatological examination can reveal thin skin that bruises
easily. A history (or family history) of spontaneous bowel or
uterine rupture may also be elicited.
Management
Owing in large part to its rarity, the management for vEDS is
yet to be codified in definitive guidelines. Centres with expe-
rience of treating vEDS report that management is optimised
through development of multidisciplinary teams comprising
physicians, vascular surgeons and general surgeons [29]. In
our own hospital, this team also includes respiratory, cardiol-
ogy and genetics consultants, neurosurgeons and radiologists.
Surveillance for cardiovascular complications by echocar-
diography every 3 years has been recommended [36]. A
randomised controlled trial and a subsequent observational
study using celiprolol, a combined beta-1 antagonist and
beta-2 partial agonist, showed a reduction in adverse arterial
events, so this drug is often used [37, 38]. In the absence of
clear guidelines, decisions on elective vascular procedures
have to be made on a case-by-case basis. Owing to fragility
of the blood vessels, open surgery can be challenging in
vEDS, and so elective procedures are performed less frequent-
ly than in other diseases affecting connective tissues. The rise
of endovascular approaches, however, may alter this balance
in the future [39].
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For patients that have suffered from gastrointestinal com-
plications, a recent systematic review suggested that end
ileostomies or ileorectal anastomoses are preferable over co-
lostomies due to the risk of reperforation and anastomotic
leaks with the latter [40].
Loeys-Dietz Syndrome
Genetics
Loeys-Dietz syndrome is a relative newcomer to the list of
pneumothorax-associated disorders. It was first described in
2005 as a syndrome comprising craniofacial midline fusion
defects, vascular tortuosity and neurodevelopmental defects
[41••] but is now recognised to occur in more subtle forms.
It is an autosomal dominant disorder caused by mutations in
genes of the TGFβ signalling pathway: SMAD3, TGFB2,
TGFB3, TGFBR1 and TGFBR2 [42].
Clinical features
We reported pneumothorax as the presenting feature in an
individual with normal neurodevelopment ultimately con-
firmed to have Loeys-Dietz syndrome (LDS) with a
TGFBR2 mutation [33•]. It is important to make an early di-
agnosis to permit preventive treatment of the cardiovascular
risk. Arterial dissection may arise in a broader range of vessels
in patients with LDS; this should therefore be considered even
if the former arises below the diaphragm [43]. Other clinical
features suggestive of LDS include midline fusion defects,
with severely affected individuals having hypertelorism or
cleft lip, while milder cases may have only a bifid uvula.
The latter can easily been seen in the respiratory clinic by
inspecting the oropharynx (Fig. 1b). Other features include
skeletal abnormalities (pectus excavatum or carinatum, scoli-
osis, joint laxity or contracture) and skin changes (easy bruis-
ing, translucency and dystrophic scars) [41••]. A lack of ocular
changes distinguishes LDS from Marfan syndrome.
Fig. 1 Syndromic causes of pneumothorax. a Vascular Ehlers Danlos
syndrome. Lung parenchyma stained with haematoxylin and eosin.
Magnification × 16 objective. Note hemosiderin-laden intraalveolar
macrophages, suggesting prior pulmonary haemorrhage, and foci of
intraalveolar organisation. b Loeys-Dietz syndrome. Bifid uvula.
Reproduced with permission from [33•]. c Lymphangioleiomyomatosis.
Axial CT image of a patient with lymphangioleiomyomatosis. Note the
many thin-walled cysts of varying size. Bilateral recurrent
pneumothoraces following previously bilateral pleurodesis. d Birt-
Hogg-Dubé syndrome. Axial CT image of the lung bases of a patient
with Birt-Hogg-Dubé syndrome. Note the irregular, multiseptated cysts
that of frequently subpleural. Small contralateral anterior pneumothorax
Table 2 The Beighton score of hypermobility. Adapted from [35]
Beighton score
1 point is given for each of the following tests. Tests 1–4 are performed on
both right and left sides so can score a maximum of 2 points each. The
maximum possible score is 9. The maximum normal score is
considered to be 5.
(1) Passive dorsiflexion of the little finger beyond 90° with the forearm
flat on the table
(2) Passive opposition of the thumb to the flexor aspect of the forearm
(3) Hyperextension of the elbow beyond 10°
(4) Hyperextension of the knee beyond 10°
(5) Forward flexion of the trunk so the palms of the hands rest easily on
the floor
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It has been suggested that LDS requires evidence of aneu-
rysm or dissection and a pathogenic mutation in any of the
genes outlined above [43]. This guidance expands on previous
reports suggesting that only mutations in TGFBR1 and
TGFBR2 be considered [44]. Current guidance stresses that
craniofacial features and cutaneous features may be very mild;
however, the presence of severe craniofacial deformity pre-
dicts a poor prognosis [44].
Management
As with other connective tissue disorders, cardiovascular sur-
veillance is important in LDS. Echocardiography should be
performed at least annually and more regularly in severely
affected individuals. Since a wider range of vessels can be
affected, we recommend periodic magnetic resonance angiog-
raphy from the head to lower limbs in selected patients.
Prophylactic antihypertensives are often used albeit with a
smaller evidence base than exists for Marfan syndrome.
Angiotensin receptor blockers have the theoretical added ben-
efit of antagonising the TGFβ pathway offering a scientifical-
ly plausible advantage over beta-blockers; as yet, head to head
trials are lacking. Unlike Marfan syndrome, dissections have
frequently been reported with aneurysmal diameters of only
40 mm with prophylactic surgery advocated for aneurysms of
this size [44, 45].
α1-Antitrypsin Deficiency
Alpha1-antitrypsin deficiency is a recessive condition caused
by mutations of the SERPINA1 gene [46]. This encodes α1-
antitrypsin, which is an abundant plasma protein that inhibits
neutrophil elastase. Mutations in SERPINA1 reduce the level
of circulating α1-antitrypsin allowing uninhibited neutrophil
elastase to degrade elastin fibres in the lungs. This can cause
pulmonary emphysema even in nonsmokers and in some
cases leads to pneumothorax [47]. The retention of
polymerised α1-antitrypsin in the liver may cause cirrhosis
or hepatocellular carcinoma; hence, surveillance imaging of
the liver is recommended. In some countries, treatment with
α1-antitrypsin augmentation therapy is available, but in all
countries, lifestyle changes (smoking cessation, avoidance of
excessive alcohol) can be suggested. If necessary, lung and/or
liver transplantation can be considered.
Homocystinuria
Homocystinuria is a rare metabolic disorder that affects only 1
in 200,000 people and is inherited in an autosomal recessive
manner. Several genes can be mutated to cause the condition,
but the most common is CBS encoding cystathionine β-syn-
thase. This is responsible for the homocysteinylation of vari-
ous proteins, including fibrillin-1, which likely explains the
skeletal and ocular features homocystinuria shares with
Marfan syndrome [4]. Patients also carry amarkedly increased
risk of thrombosis, which is responsible for much of the mor-
bidity of the condition. Neurological complications including
intellectual disability and seizures, and cutaneous abnormali-
ties such as livedo reticularis or malar flush are frequently
observed [4]. There are rare reported cases in the literature
of pneumothorax due to homocystinuria [48].
Cutis Laxa
Cutis laxa is characterised by hypoelastic, sagging skin par-
ticularly prominent around the neck, armpits and groin.
Various mutant genes are reported including ATP6V0A2,
ATP7A, EFEMP2, ELN and FBLN5; the modes of inheritance
are variable, recessive forms typically being more severe [49].
The morbidity of the condition depends on the organs affect-
ed, which can include the intestines, joints, blood vessels and
lungs. In the lungs, it can cause emphysema and rarely pneu-
mothorax [50].
Syndromes Related to Tumour Suppressor
Mutations
Tuberous Sclerosis and Pulmonary
Lymphangioleiomyomatosis
Genetics
Tuberous sclerosis complex (TSC) is an autosomal dominant
disorder, which like Marfan syndrome dates back to the nine-
teenth century [51]. It is caused by loss-of-function mutations
in either of two tumour suppressor genes, TSC1 and TSC2,
which encode the proteins hamartin and tuberin respectively
[52]. These proteins form a complex that inhibits mTORC1, a
kinase involved in regulating cell proliferation, differentiation
and adhesion [53]. Perhaps unsurprisingly, the dysfunction of
these proteins leads to benign andmalignant neoplasms affect-
ing various tissues including the skin, central nervous system,
bone, kidney, heart and lung [54].
Clinical features
TSC can be diagnosed either molecularly or clinically [55].
For the molecular route, a germline pathogenic mutation in
TSC1 or TSC2 is required. Clinically, patients need two major
features or one major feature with two or more minor features
(Table 3) [55].
The most significant pulmonary manifestation of TSC is
lymphangioleiomyomatosis (LAM). When individuals with
TSC are subjected to thoracic CT imaging, up to 40% have
pulmonary cysts consistent with a diagnosis of LAM, which
Curr Pulmonol Rep (2020) 9:47–55 51
in turn is the third commonest cause of morbidity in TSC [56].
Proliferation of abnormal smooth muscle cells, so-called
‘LAM cells’, causes the formation of cysts throughout the
lungs (Fig. 1c). Around 60% of these patients experience
pneumothorax, which is often the presenting feature of
LAM [57].
Most patients with sporadic LAM (not associated with
TSC) are women of childbearing age, which reflects the sen-
sitivity of LAM cells to female sex hormones. LAM cells in
sporadic disease are commonly found to have somatic muta-
tions in TSC2 or more rarely TSC1 [58]. In patients with spo-
radic LAM, diagnosis is reached more easily if additional
features are present such as angiomyolipomas, chylous effu-
sions or lymphangioleiomyomas [59]. More recently, serum
levels of vascular endothelial growth factor-D (VEGF-D)
above 800 pg/ml have been shown to have diagnostic and
prognostic value [59]. Although the literature has suggested
that patients with sporadic LAM have more severe pulmonary
manifestations compared with TSC-associated LAM, this
may reflect lead-time bias since TSC patients will more often
be diagnosed earlier because of preemptive screening [60].
Management
Patients found to have LAM should be screened for evidence
of TSC and vice versa [58]. An early diagnosis of LAM is
particularly important because the pulmonary disease can
progress rapidly during pregnancy, and so individuals should
be provided with appropriate counselling and support [61].
We have cared for several women in whom pregnancy-
associated pneumothorax was the presenting feature of LAM.
LAM can run a benign course, and the 10-year transplant-
free survival is reported to be 86% [62]. However, it is impor-
tant to monitor women with the condition by pulmonary func-
tion testing. These tests can be challenging for patients with
severe neurological complications of TSC, and in these pa-
tients, serial measurements of VEGF-D or regular radiological
examinations may be offered instead [63, 64].
In those women who suffer progressive loss of lung func-
tion, treatment with an inhibitor mTORC1, such as sirolimus,
can be given [65]. Rarely, lung transplantation is required,
although LAM can recur in the transplanted organ [66].
Birt-Hogg Dubé Syndrome
Genetics
Folliculin is encoded by the FLCN gene, mutations of which
cause the autosomal dominant disease Birt-Hogg-Dubé syn-
drome (BHDS) [67]. Like tuberin and hamartin in TSC,
folliculin regulates mTORC1 although the precise mechanism
is still incompletely understood. The large FLCN gene con-
tains 14 exons and approximately 150 different pathogenic
FLCN mutations have been identified [67]. These span the
entire coding region, although several mutational ‘hot spots’
exist. Of these, a polycytosine tract in exon 11 is the most
important and accounts for nearly 50% of allFLCNmutations,
either as inserted (c.1285dupC) or deleted (c.1285delC) resi-
dues [68].
Clinical features
In contrast to tuberous sclerosis, Birt-Hogg-Dubé syndrome
predominantly affects only a handful of tissues: the kidney,
skin and lungs. In the kidney, it can manifest as renal cancers
presenting typically in the fifth decade [67]. Only around a
quarter of patients develop renal cancers because further ran-
dom somatic mutations are required for oncogenesis, the so-
called two-hit hypothesis [69]. Most of the renal tumours in
Birt-Hogg-Dubé syndrome are atypical hybrid oncocytoma-
chromophobe or chromophobe types. This is in contradistinc-
tion to other familial renal cancer syndromes, such as von-
Hippel-Lindau syndrome in which more typical clear cell can-
cers are frequently seen [70]. An important consequence of
this is that the atypical tumours of Birt-Hogg-Dubé syndrome
are less easily detected by renal ultrasound scanning and can
be missed unless renal MRI scanning is performed.
Individuals with Birt-Hogg-Dubé syndrome can also have
skin changes including fibrofolliculomas, trichodiscomas,
perifollicular fibromas and acrochordons. The most common
are fibrofolliculomas, which are a useful marker of the condition
when detected in the clinic. Respiratory physicians should be
familiar with these lesions and when in doubt seek dermatolog-
ical assistance. Fibrofolliculomas are benign tumours of the
Table 3 Clinical diagnostic criteria for tuberous sclerosis. Adapted
from [55]
Major features:
(1) Angiofibromas (≥ 3) or fibrous cephalic plaque
(2) Cardiac rhabdomyoma
(3) Cortical dysplasias, including tubers and cerebral white matter
migration lines
(4) Subependymal giant cell astrocytoma
(5) Subependymal nodules
(6) Hypomelanotic macules (3 to >5 mm in diameter)
(7) Shagreen patch
(8) Multiple retinal nodular hamartomas
(9) Renal angiomyolipoma
(10) Ungual fibromas (≥ 2)
(11) Lymphangioleiomyomatosis (LAM)
Minor features:
(1) Numerous 1- to 3-mm hypopigmented macules scattered over regions
of the body such as the arms and legs (“Confetti skin lesions”)
(2) Dental enamel pits (> 3)
(3) Intraoral fibromas (≥ 2)
(4) Multiple renal cysts
(5) Non-renal hamartomas
(6) Retinal achromic patch
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follicular epithelium that present as smooth, 2–4 mm, white or
flesh-coloured papules found on the face, ears and upper torso.
The lung manifestations are the most commonly observed
features of Birt-Hogg-Dubé syndrome, pulmonary cysts being
almost universal [67]. Irregular, sometimes septated cysts oc-
cur characteristically toward the bases or at least below the
level of the carina and tend to be medially sited. This distin-
guishes Birt-Hogg-Dubé syndrome from LAM which has
round cysts that are more evenly spread throughout the lung
fields (Fig. 1d) [67]. Although the pathogenesis of these cysts
is uncertain, the ‘stretch theory’ arose because folliculin plays
a role in regulating cell-cell adhesion through the formation of
the folliculin-plakophilin-4 complex, perhaps independent of
its role in mTORC1 regulation [71]. It is hypothesised that a
lack of folliculin increases cell-cell adhesion and that, over
time, the stress induced by respiratory movement causes the
alveolar space to rupture and form cysts [71, 72]. Interestingly,
this predicts that cyst numbers or size will increased over time,
but evidence for this is currently lacking. Pneumothoraces can
occur because the cysts are frequently subpleural. Indeed,
Birt-Hogg-Dubé syndrome is by far the most common genetic
cause of familial pneumothorax, accounting for around 50%
of cases in which a diagnosis is made, ahead of Marfan syn-
drome and vEDS. The age at which Birt-Hogg-Dubé syn-
drome patients present with pneumothoraces is around a de-
cade earlier than the age they develop renal carcinomas.
Management
If a diagnosis of Birt-Hogg-Dubé syndrome is made at the
time of the pneumothorax, patients can be offered renal sur-
veillance imaging (ideally with annual MRI) and thereby have
early renal cancers diagnosed. This is especially appealing
because these renal tumours tend to be curable if excised be-
fore reaching 3 cm. If the tumour is 3 cm or less then a partial
nephrectomy can be performed, but for larger tumours, a full
nephrectomy may be indicated [73]. At present, it is recom-
mended that patients are screened annually from the age of
20 years [73], but recently, a 14-year old with Birt-Hogg-Dubé
syndrome was reported as having developed a renal cancer,
and so this guidance might change [74].
Fibrofolliculomas are benign, and so treatment is only un-
dertaken for cosmetic reasons. Topical anti-mTORC1 has thus
far proved unsuccessful in treating the lesions [75] and
fibrofolliculomas often recur following laser therapy [76].
Electrocoagulation followed by curettage is therefore the treat-
ment of choice [77].
Conclusion
Pneumothorax is an important presenting feature in several
genetic disorders that carry high risks of morbidity and
mortality later in life. By far, the most common syndromic
cause of pneumothorax is Birt-Hogg-Dubé syndrome.
Careful clinical assessment of spontaneous pneumothorax
can identify this and many other conditions to enable life-
saving interventions to be commenced. Because many of
these conditions have autosomal inheritance, the diagnosis
of one proband frequently leads to the diagnosis of many
affected but subclinical family members, thus widening the
potential clinical benefit. Respiratory physicians must there-
fore be alert to these diseases and their diagnostic
implications.
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